Mirror‐Image Phage Display for the Selection of D‐Amino Acid Peptide Ligands as Potential Therapeutics

Abstract

AbstractIn neurodegenerative diseases like Alzheimer's disease (AD), endogenous proteins or peptides aggregate with themselves. These proteins may lose their function or aggregates and/or oligomers can obtain toxicity, causing injury or death to cells. Aggregation of two major proteins characterizes AD. Amyloid‐β peptide (Aβ) is deposited in amyloid plaques within the extracellular space of the brain and Tau in so‐called neurofibrillary tangles in neurons. Finding peptide ligands to halt protein aggregation is a promising therapeutical approach. Using mirror‐image phage display with a commercially available, randomized 12‐mer peptide library, we have selected D‐amino acid peptides, which bind to the Tau protein and modulate its aggregation in vitro. Peptides can bind specifically and selectively to a target molecule, but natural L‐amino acid peptides may have crucial disadvantages for in vivo applications, as they are sensitive to protease degradation and may elicit immune responses. One strategy to circumvent these disadvantages is the use of non‐naturally occurring D‐amino acid peptides as they exhibit increased protease resistance and generally do not activate the immune system. To perform mirror‐image phage display, the target protein needs to be synthesized as D‐amino acid version. If the target protein sequence is too long to be synthesized properly, smaller peptides derived from the full length protein can be used for the selection process. This also offers the possibility to influence the binding region of the selected D‐peptides in the full‐length target protein. Here we provide the protocols for mirror‐image phage display selection on the PHF6* peptide of Tau, based on the commercially available Ph.D.™‐12 Phage Display Peptide Library Kit, leading to D‐peptides that also bind the full length Tau protein (Tau441), next to PHF6*. In addition, we provide protocols and data for the first characterization of those D‐peptides that inhibit Tau aggregation in vitro. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Mirror image phage display selection against D‐PHF6* fibrilsSupport Protocol 1: Single phage ELISABasic Protocol 2: Sequencing and D‐peptide generationBasic Protocol 3: Thioflavin‐T (ThT) test to control inhibition of Tau aggregationSupport Protocol 2: Purification of full‐length Tau proteinBasic Protocol 4: ELISA to demonstrate the binding of the generated D‐peptides to PHF6* and full‐length Tau fibrils